دندان سوم؛ افسانه یا واقعیت؟

Mechanism

USAG-1 (SOSTDC1/ectodin/WISE) is a bifunctional BMP and Wnt antagonist; the paper reports that BMP-directed blockade, rather than Wnt blockade, is what increases tooth number.

Key preclinical findings (Murashima-Suginami 2021)

• Genetic rescue. USAG-1 knockout rescued tooth formation in Msx1-null mice (all 3 surviving double-KO mice had normal maxillary M3) and in EDA1-null mice, where about 75% of the controls had mandibular molar hypodontia. Msx1 double-KO was rare (3 of 151 offspring, vs. 1/16 expected), and the cleft palate persisted.
• Antibody panel. Five monoclonal antibodies (#12, #16, #37, #48, #57) fall into BMP-only, Wnt-only, or dual-blocking classes. Those blocking Wnt or both (#12, #16, #48) were linked to low birth and survival rates in the offspring.
• Efficacy. BMP-selective #37 reversed molar hypodontia in EDA1-null mice at a high rate and in a dose-dependent way, after a single intraperitoneal dose (16 µg/g) given to pregnant dams at E13. #57 induced supernumerary teeth in wild-type mice. Exact rescue percentages are in Fig. 3B and are not stated in the text. I could not extract them, so check the figure before quoting numbers.
• Ferret (diphyodont model). #37 produced a lingual maxillary incisor resembling a third dentition, but it required 5× the dose (80 vs 16 µg/g), three administrations and immunosuppression, and the root was short.

Limitations to emphasise

• Phenotype selectivity. The authors state that it did not cure all agenesis types and that causative-gene mutations may serve as patient-selection biomarkers.
• Safety signal. Non-selective neutralisation had a safety problem in mice, which is why the BMP-selective clone was chosen.
• Conflict of interest. The study was funded by Toregem BioPharma, and the institutions hold a related patent.
• Species. The authors themselves call for further non-rodent work (dogs, pigs, suncus).
• Other species. Dentistry.co.uk reports that dog data also showed third-generation teeth. I could not verify this in a peer-reviewed paper.

Clinical programme (TRG035, humanised anti-USAG-1)

Interpretation and trends

• Efficacy in humans: none. TRG035 has not been shown to regenerate teeth in humans.
• Target population. Severe congenital hypodontia (six or more missing permanent teeth) is the next-stage focus, not periodontal or traumatic tooth loss. Extension to acquired loss is an aspiration only.
• Timeline. The team's 2030 target for general use should be treated as provisional.
• Epidemiology. Tooth number is abnormal in about 1% of people. Complete edentulism affects 7% of adults 20+ and 23% of those over 60 (WHO).
• Alternatives, all earlier-stage. Stem-cell/bioengineered teeth (the Tufts pig-human hybrid study), scaffold-based organoid approaches (KCL), and enamel and dentine regeneration biomaterials.

What to watch for

Phase I safety data and the anti-drug antibody rate, the Phase IIa dosing and eruption outcomes, whether root development and occlusal function are acceptable, and whether efficacy holds across different agenesis genotypes.